Συγγραφείς:
Richter, J.
Lübking, A.
Söderlund, S.
Lotfi, K.
Markevärn, B.
Själander, A.
Stenke, L.
Deneberg, S.
Ahlstrand, E.
Myhr-Eriksson, K.
Panayiotidis, P.
Gedde-Dahl, T.
Žáčková, D.
Mayer, J.
Olsson-Strömberg, U.
Mahon, F.-X.
Saussele, S.
Hjorth-Hansen, H.
Koskenvesa, P.
Λέξεις-κλειδιά:
BCR ABL protein; BCR ABL1 protein; protein tyrosine kinase inhibitor; unclassified drug; BCR ABL protein; protein kinase inhibitor, Article; cancer patient; cause of death; chronic myeloid leukemia; clinical practice; drug withdrawal; follow up; human; incidence; leukemia relapse; leukemia remission; mismatch repair; molecular genetics; molecular pathology; outcome assessment; patient monitoring; prediction; real time polymerase chain reaction; stem cell transplantation; treatment duration; chronic myeloid leukemia; clinical trial (topic); diagnosis; epidemiology; Europe; genetics; pathology; procedures; prognosis; remission; time factor; treatment withdrawal; tumor recurrence, Clinical Trials as Topic; Europe; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Remission Induction; Time Factors; Withholding Treatment
